177 related articles for article (PubMed ID: 30977266)
1. Hyperammonemia after capecitabine associated with occult impairment of the urea cycle.
Chu G; Salzman J
Cancer Med; 2019 May; 8(5):1996-2004. PubMed ID: 30977266
[TBL] [Abstract][Full Text] [Related]
2. A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer.
Fang W; Fu Y; Wei J
Curr Drug Saf; 2018; 13(1):55-58. PubMed ID: 28782476
[TBL] [Abstract][Full Text] [Related]
3. Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
Di Federico A; Nuvola G; Sisi M; Lenzi B; Nobili E; Campana D
Anticancer Drugs; 2020 Nov; 31(10):1103-1105. PubMed ID: 32826413
[TBL] [Abstract][Full Text] [Related]
4. Cloning and characterization of human ORNT2: a second mitochondrial ornithine transporter that can rescue a defective ORNT1 in patients with the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, a urea cycle disorder.
Camacho JA; Rioseco-Camacho N; Andrade D; Porter J; Kong J
Mol Genet Metab; 2003 Aug; 79(4):257-71. PubMed ID: 12948741
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
[TBL] [Abstract][Full Text] [Related]
6. [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer].
Nakamura M; Kobashikawa K; Tamura J; Takaki R; Ohshiro M; Matayoshi R; Hirata T; Kinjyo F; Fujita J
Nihon Shokakibyo Gakkai Zasshi; 2009 Dec; 106(12):1744-50. PubMed ID: 19966516
[TBL] [Abstract][Full Text] [Related]
7. [Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis].
Iida T; Wagatsuma K; Tani M; Sasaki H; Naganawa Y; Isshiki H; Murakami K; Satoh S; Shimizu H; Kaneto H
Nihon Shokakibyo Gakkai Zasshi; 2015 Feb; 112(2):287-96. PubMed ID: 25748155
[TBL] [Abstract][Full Text] [Related]
8. [Risk factors for hyperammonemia during mFOLFOX6 treatment].
Misumi N; Goto T; Miyoshi T; Hiraike M; Shirasawa H; Saito O; Nishino T; Oudo M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):483-7. PubMed ID: 23848016
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Hyperammonemia Induced by Chemotherapy with 5-Fluorouracil for Metastatic Colon Cancer].
Tokuyama S; Fukunaga M; Konishi K; Honda S; Yukimoto R; Okamoto A; Saito A; Okada K; Ota H; Yokoyama S; Miki H; Kobayashi K
Gan To Kagaku Ryoho; 2018 Apr; 45(4):743-745. PubMed ID: 29650854
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.
Thomas SA; Tomeh N; Theard S
Anticancer Res; 2015 Dec; 35(12):6761-3. PubMed ID: 26637893
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects of urea cycle dysfunction and altered brain energy metabolism on modulation of glutamate receptors and transporters in acute and chronic hyperammonemia.
Natesan V; Mani R; Arumugam R
Biomed Pharmacother; 2016 Jul; 81():192-202. PubMed ID: 27261594
[TBL] [Abstract][Full Text] [Related]
12. 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Advani PP; Fakih MG
Anticancer Res; 2011 Jan; 31(1):335-8. PubMed ID: 21273620
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Boilève A; Thomas L; Lillo-Le Louët A; Gaboriau L; Chouchana L; Ducreux M; Malka D; Boige V; Hollebecque A; Hillaire-Buys D; Jozwiak M
Eur J Cancer; 2020 Apr; 129():32-40. PubMed ID: 32120273
[TBL] [Abstract][Full Text] [Related]
14. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine induced colitis.
Maggo G; Grover SC; Grin A
Pathol Res Pract; 2014 Sep; 210(9):606-8. PubMed ID: 24947412
[TBL] [Abstract][Full Text] [Related]
16. Antagonizing effect of AP-1 on glucocorticoid induction of urea cycle enzymes: a study of hyperammonemia in carnitine-deficient, juvenile visceral steatosis mice.
Saheki T; Li MX; Kobayashi K
Mol Genet Metab; 2000 Dec; 71(4):545-51. PubMed ID: 11136545
[TBL] [Abstract][Full Text] [Related]
17. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
[TBL] [Abstract][Full Text] [Related]
18. Hyperammonemia in Inherited Metabolic Diseases.
Ribas GS; Lopes FF; Deon M; Vargas CR
Cell Mol Neurobiol; 2022 Nov; 42(8):2593-2610. PubMed ID: 34665389
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine in advanced gastric cancer.
Okines A; Chau I; Cunningham D
Expert Opin Pharmacother; 2007 Nov; 8(16):2851-61. PubMed ID: 17956204
[TBL] [Abstract][Full Text] [Related]
20. Case report of capecitabine toxicity and use of uridine triacetate.
Oliver WD; Duffy AP; Hausner PF
J Oncol Pharm Pract; 2019 Mar; 25(2):470-473. PubMed ID: 28942723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
